R&D CAMP4 on a new class of ASO in gene under expression CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study
News CAMP4 raises $100m to take lead RNA drugs into clinic Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
